Evidence map›Paper›PMID 34472584›Full record

ArticleBioscience reports2021

miRNome profiling in Duchenne muscular dystrophy; identification of asymptomatic and manifesting female carriers.

Nahla O Mousa, Ahmed A Sayed, Nagia Fahmy, Mariam G Elzayat, Usama Bakry, Ahmed Abdellatif, Waheed K Zahra, Ahmed Osman

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Nahla O MousaBiotechnology Department, Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology, Borg Al Arab 21934, Egypt.
Ahmed A SayedGenomics Program, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.
Nagia FahmyNeuromuscular Unit, Neuropsychiatry Department, Faculty of Medicine Ain Shams University, Cairo 11566, Egypt.
Mariam G ElzayatGenomics Program, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.
Usama BakryGenomics Program, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.
Ahmed AbdellatifBiology Department, and Biotechnology program, School of Sciences and Engineering, The American University in Cairo, School of Sciences and Engineering, Cairo 11835, Egypt.
Waheed K ZahraMathematics Department, Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology, Borg Al Arab 21934, Egypt.
Ahmed OsmanBiotechnology Department, Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology, Borg Al Arab 21934, Egypt.ORCID 0000-0002-3506-8254
Ain Shams University · EGChildren Cancer Hospital · EGAmerican University in Cairo · EGCairo University · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder that occurs due to inactivating mutations in DMD gene, leading to muscular dystrophy. Prediction of pathological complications of DMD and the identification of female carriers are important research points that aim to reduce disease burden. Herein, we describe a case of a late DMD patient and his immediate female family members, who all carry same DMD mutation and exhibited varied degrees of symptoms. In our study, we sequenced the whole miRNome in leukocytes and plasma of the family members and results were validated using real-time PCR. Our results highlighted the role of miR-409-3p, miR-424-5p, miR-144-3p as microRNAs that show correlation with the extent of severity of muscular weakness and can be used for detection of asymptomatic carriers. Cellular and circulating levels of miR-494-3p had shown significant increase in symptomatic carriers, which may indicate significant roles played by this miRNA in the onset of muscular weakness. Interestingly, circulating levels of miR-206 and miR-410-3p were significantly increased only in the severely symptomatic carrier. In conclusion, our study highlighted several miRNA species, which could be used in predicting the onset of muscle and/or neurological complications in DMD carriers.

Indexed as

Gene Expression ProfilingHeterozygoteMutationTranscriptomeAdultAsymptomatic DiseasesChildDNA Mutational AnalysisDystrophinFemaleGenetic Predisposition to DiseaseHeredityHigh-Throughput Nucleotide SequencingHumansMaleMicroRNAsDMD protein, humanDystrophinMicroRNAsMIRN144 microRNA, humanMIRN409 microRNA, humanMIRN424 microrna, humanCarriersDuchenne muscular dystrophymicroRNANext generation sequencing

Identifiers

PMID34472584
PMCPMC8450315
OpenAlexW3196739965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.